These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 33674146)

  • 21. Minimal Residual Disease in Multiple Myeloma: an Important Tool in Clinical Trials.
    Gozzetti A; Bocchia M
    Rev Recent Clin Trials; 2022; 17(1):9-10. PubMed ID: 34814822
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monitoring minimal residual disease in the bone marrow using next generation sequencing.
    Rustad EH; Boyle EM
    Best Pract Res Clin Haematol; 2020 Mar; 33(1):101149. PubMed ID: 32139014
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Standardisation of minimal residual disease in multiple myeloma.
    Innao V; Allegra A; Russo S; Gerace D; Vaddinelli D; Alonci A; Allegra AG; Musolino C
    Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 28671297
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Personalized immunoglobulin aptamers for detection of multiple myeloma minimal residual disease in serum.
    Tapia-Alveal C; Olsen TR; Worgall TS
    Commun Biol; 2020 Dec; 3(1):781. PubMed ID: 33335255
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma.
    Medina A; Puig N; Flores-Montero J; Jimenez C; Sarasquete ME; Garcia-Alvarez M; Prieto-Conde I; Chillon C; Alcoceba M; Gutierrez NC; Oriol A; Rosinol L; Bladè J; Gironella M; Hernandez MT; Gonzalez-Calle V; Cedena MT; Paiva B; San-Miguel JF; Lahuerta JJ; Mateos MV; Martinez-Lopez J; Orfao A; Gonzalez M; Garcia-Sanz R
    Blood Cancer J; 2020 Oct; 10(10):108. PubMed ID: 33127891
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment.
    Nishihori T; Song J; Shain KH
    Curr Hematol Malig Rep; 2016 Apr; 11(2):118-26. PubMed ID: 26898557
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Minimal Residual Disease Assessment in Multiple Myeloma by Multiparametric Flow Cytometry.
    Rihova L; Vsianska P; Bezdekova R; Kralova R; Penka M; Krejci M; Pour L; Hájek R
    Klin Onkol; 2017; 30(Supplementum2):21-28. PubMed ID: 28903567
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma.
    Martinez-Lopez J; Lahuerta JJ; Pepin F; González M; Barrio S; Ayala R; Puig N; Montalban MA; Paiva B; Weng L; Jiménez C; Sopena M; Moorhead M; Cedena T; Rapado I; Mateos MV; Rosiñol L; Oriol A; Blanchard MJ; Martínez R; Bladé J; San Miguel J; Faham M; García-Sanz R
    Blood; 2014 May; 123(20):3073-9. PubMed ID: 24646471
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular Diagnostics of Plasma Cell Neoplasms.
    Fitzpatrick MJ; Murali MR; Nardi V
    Surg Pathol Clin; 2023 Jun; 16(2):401-410. PubMed ID: 37149365
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma.
    Flores-Montero J; Sanoja-Flores L; Paiva B; Puig N; García-Sánchez O; Böttcher S; van der Velden VHJ; Pérez-Morán JJ; Vidriales MB; García-Sanz R; Jimenez C; González M; Martínez-López J; Corral-Mateos A; Grigore GE; Fluxá R; Pontes R; Caetano J; Sedek L; Del Cañizo MC; Bladé J; Lahuerta JJ; Aguilar C; Bárez A; García-Mateo A; Labrador J; Leoz P; Aguilera-Sanz C; San-Miguel J; Mateos MV; Durie B; van Dongen JJM; Orfao A
    Leukemia; 2017 Oct; 31(10):2094-2103. PubMed ID: 28104919
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Minimal residual disease in multiple myeloma: why, when, where.
    Yee AJ; Raje N
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):37-45. PubMed ID: 34889430
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Prognostic significance of sequencing-based MRD detection in multiple myeloma].
    Takamatsu H
    Rinsho Ketsueki; 2015 Aug; 56(8):989-96. PubMed ID: 26345557
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.
    Anderson KC; Auclair D; Kelloff GJ; Sigman CC; Avet-Loiseau H; Farrell AT; Gormley NJ; Kumar SK; Landgren O; Munshi NC; Cavo M; Davies FE; Di Bacco A; Dickey JS; Gutman SI; Higley HR; Hussein MA; Jessup JM; Kirsch IR; Little RF; Loberg RD; Lohr JG; Mukundan L; Omel JL; Pugh TJ; Reaman GH; Robbins MD; Sasser AK; Valente N; Zamagni E
    Clin Cancer Res; 2017 Aug; 23(15):3980-3993. PubMed ID: 28428191
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New criteria for response assessment: role of minimal residual disease in multiple myeloma.
    Paiva B; van Dongen JJ; Orfao A
    Blood; 2015 May; 125(20):3059-68. PubMed ID: 25838346
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Minimal residual disease analysis in myeloma - when, why and where.
    Yanamandra U; Kumar SK
    Leuk Lymphoma; 2018 Aug; 59(8):1772-1784. PubMed ID: 29019452
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis.
    Gambella M; Omedé P; Spada S; Muccio VE; Gilestro M; Saraci E; Grammatico S; Larocca A; Conticello C; Bernardini A; Gamberi B; Troia R; Liberati AM; Offidani M; Rocci A; Palumbo A; Cavo M; Sonneveld P; Boccadoro M; Oliva S
    Cancer; 2019 Mar; 125(5):750-760. PubMed ID: 30561775
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interlaboratory Analytical Validation of a Next-Generation Sequencing Strategy for Clonotypic Assessment and Minimal Residual Disease Monitoring in Multiple Myeloma.
    Medina A; Jiménez C; Puig N; Sarasquete ME; Flores-Montero J; García-Álvarez M; Prieto-Conde I; Chillón C; Alcoceba M; González-Calle V; Gutiérrez NC; Jacobsen A; Vigil E; Hutt K; Huang Y; Orfao A; González M; Miller J; García-Sanz R
    Arch Pathol Lab Med; 2022 Jul; 146(7):862-871. PubMed ID: 34619755
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Upgraded Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma.
    Yao Q; Bai Y; Orfao A; Kumar S; Chim CS
    J Mol Diagn; 2020 May; 22(5):679-684. PubMed ID: 32151713
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Comparison of next-generation flow cytometry and next-generation sequencing in the assessment of minimal residual disease in multiple myeloma].
    Wang QQ; Yao L; Zhu MQ; Yan LZ; Jin S; Shang JJ; Shi XL; Zhai YY; Yan S; Yao WQ; You HY; Wu DP; Fu CC
    Zhonghua Xue Ye Xue Za Zhi; 2023 Apr; 44(4):328-332. PubMed ID: 37357003
    [No Abstract]   [Full Text] [Related]  

  • 40. Multiple myeloma: disease response assessment.
    Zamagni E; Tacchetti P; Terragna C; Cavo M
    Expert Rev Hematol; 2016 Sep; 9(9):831-7. PubMed ID: 27409577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.